Immunotherapy improves survival for people with relapsed mesothelioma

It was recently reported by Cancer Research UK, that people with an aggressive form of lung cancer that’s come back after treatment, leaving them with limited options, could live longer when treated with an immunotherapy currently available for several types of cancer.

The trial, funded by Cancer Research UK’s Stand Up To Cancer campaign, found that the immunotherapy drug nivolumab increased survival and made the disease more stable for patients with relapsed mesothelioma when compared to those in the placebo group. This is the first study to show that a treatment has been able to improve survival in patients with mesothelioma that’s come back after chemotherapy.

You can read the full article on the Cancer Research UK website.